11-Keto-beta-boswellic acid

SKU: orb1220091

Description

11-Keto-beta-boswellic acid, a novel Nrf2 activator, and a selective 5-lipoxygenase (5-LOX) inhibitor; it exerts dose dependent cardioprotective effect manifested by dose-dependent reduction in serum lactate dehydrogenaseA total of ten transformed compounds were isolated and purified, and their chemical structures were characterized as 7β-hydroxy-11-keto-β-boswellic acid; 7β, 15α±-dihydroxy-11-keto-β-boswellic acid ; 7β, 16β-dihydroxy-11-keto-β-boswellic acid; 7β, 16α±-dihydroxy-11-keto-β-boswellic acid; 7β, 22β-dihydroxy-11-keto-β-boswellic acid; 7β, 21β-dihydroxy-11-keto-β-boswellic acid; 7β, 20β-dihydroxy-11-keto-β-boswellic acid; 7β, 30-dihydroxy-11-keto-β-boswellic acid; 3α±, 7β-dihydroxy-11-oxours-12-ene-24, 30-dioic acid and 3α±, 7β-dihydroxy-30-(2-hydroxypropanoyloxy)-11-oxours-12-en-24-oic acid by various spectroscopic methods. The biotransformation processes include hydroxylation, oxidation and esterification. Primary structure-activity relationships (SAR) of inhibitory effects on NO production in RAW 264.7 macrophage cells are discussed.

Key Properties

• CAS Number: 17019-92-0
• MW: 470.68
• Purity: >98% (HPLC)
• Formula: C₃₀H₄₆O₄
• SMILES: [H][C@@]12[C@@H](C)[C@H](C)CC[C@]1(C)CC[C@]1(C)C2=CC(=O)[C@]2([H])[C@@]3(C)CC[C@@H](O)[C@](C)(C(O)=O)[C@]3([H])CC[C@@]12C
• Target: Lipoxygenase
• Solubility: In Vitro: DMSO : 50 mg/mL (106.23 mM)

Bioactivity

• In Vivo:
  Animal model: Streptozotocin (HY-13753)-induced diabetic rats. Dosage: 1-10 mg/kg. Administration: p.o. , for 21 days. Result: Reduced blood glucose level. Reduced the serum SGPT, SGOT, ALP, and serum creatinine level. Decreased serum MDA level and increased serum SOD levels.

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Quick Database Links

Gene Symbol

Lipoxygenase